Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.

G. Duthoit,Johanne Silvain,Eloi Marijon,Gregory Ducrocq,Antoine Lepillier,Corinne Frere,Solohaja-Faniaha Dimby,Batric Popovic,Nicolas Lellouche,Isabelle Martin-Toutain,Christian Spaulding,Eric Brochet,David Attias,Jacques Mansourati,Luc Lorgis,Didier Klug,N. Zannad,Marie Hauguel-Moreau,N. Braik,Sandrine Deltour,Alexandre Ceccaldi,Hui Wang,Nadjib Hammoudi,Delphine Brugier,Eric Vicaut,Jean-Michel Juliard,Gilles Montalescot

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.

2020

Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagul...

Keywords:

Internal medicine
Contraindication
Atrial Appendage
Percutaneous
Rivaroxaban
Clopidogrel
Cardiology
left atrial
Atrial fibrillation
Medicine
Appendage

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations